Xuewen Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuewen Wu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Jian Song
Xiangya Hospital, Central South University
5 shared publicationsLingyun Mei
Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China
5 shared publications- Yong Feng
Department of Otorhinolaryngology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China
5 shared publications Lu Wang
Department of Otolaryngology-Head and Neck Surgery & National Clinical Research Center for Geriatric Disorders & Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
4 shared publicationsHong Sun
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China
3 shared publicationsShaobing Xie
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, PR China
3 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Springer Nature in Cell Death & Disease
Targeting SHMT2 reverses lactate-driven CAF-mediated T-cell exclusion and sensitizes HNSCC to anti-PD-1 immunotherapy
Resistance to PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) is frequently attributed to an “immune-excluded” tumor microenvironment (TME); however, the tumor-intrinsic metabolic drivers orchestrating this spatial remodeling remain poorly defined. Here, we identify serine hydroxymethyltransferase 2 (SHMT2) as a critical determinant of the immunosuppressive stromal niche. SHMT2 is aberrantly overexpressed in malignant cells, and its high expression correlates with a cancer-associated fibroblast (CAF)-rich, T-cell-excluded phenotype in HNSCC cohorts. While SHMT2 deficiency does not alter tumor growth in immunodeficient mice, it markedly suppresses tumor progression in immunocompetent hosts, suggesting an immune-dependent therapeutic effect. Integrated single-cell and spatial profiling reveal that SHMT2 loss reduces CAF accumulation and disrupts the CAF-mediated physical barrier, facilitating robust infiltration of CD4⁺ and CD8⁺ T cells into the tumor parenchyma, without inducing a general reduction in other immunosuppressive immune populations. Mechanistically, SHMT2-driven one-carbon metabolism maintains the S-adenosylmethionine (SAM) pool, which promotes H3K4me3 enrichment at the LDHA promoter to epigenetically activate its transcription. The resulting SHMT2–SAM–LDHA axis elevates lactate secretion, which acts as a paracrine signal to trigger CAF activation and spatial accumulation. Furthermore, pharmacological targeting of the SHMT2-dependent axis using SHMT-IN-2 effectively suppresses lactate-associated CAF remodeling and synergizes with anti-PD-1 therapy in vivo. These findings suggest that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
- 19 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessTargeting SHMT2 reverses lactate-driven CAF-mediated T-cell exclusion and sensitizes HNSCC to anti-PD-1 immunotherapy
Resistance to PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) is frequently attributed to an “immune-excluded” tumor microenvironment (TME); however, the tumor-intrinsic metabolic drivers orchestrating this spatial remodeling remain poorly defined. Here, we identify serine hydroxymethyltransferase 2 (SHMT2) as a critical determinant of the immunosuppressive stromal niche. SHMT2 is aberrantly overexpressed in malignant cells, and its high expression correlates with a cancer-associated fibroblast (CAF)-rich, T-cell-excluded phenotype in HNSCC cohorts. While SHMT2 deficiency does not alter tumor growth in immunodeficient mice, it markedly suppresses tumor progression in immunocompetent hosts, suggesting an immune-dependent therapeutic effect. Integrated single-cell and spatial profiling reveal that SHMT2 loss reduces CAF accumulation and disrupts the CAF-mediated physical barrier, facilitating robust infiltration of CD4⁺ and CD8⁺ T cells into the tumor parenchyma, without inducing a general reduction in other immunosuppressive immune populations. Mechanistically, SHMT2-driven one-carbon metabolism maintains the S-adenosylmethionine (SAM) pool, which promotes H3K4me3 enrichment at the LDHA promoter to epigenetically activate its transcription. The resulting SHMT2–SAM–LDHA axis elevates lactate secretion, which acts as a paracrine signal to trigger CAF activation and spatial accumulation. Furthermore, pharmacological targeting of the SHMT2-dependent axis using SHMT-IN-2 effectively suppresses lactate-associated CAF remodeling and synergizes with anti-PD-1 therapy in vivo. These findings suggest that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
- Open Access
- 9 July 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (3)
Embryonic stem cell-derived small extracellular vesicles alleviate lead-induced cochlear spiral ganglion neurons injury by activating PI3 K/AKT signaling pathway
Objective: Embryonic stem cell (ESC)-derived small extracellular vesicles (sEVs) exhibit considerable potential as an innovative therapeutic approach in the fields of regenerative medicine and disease management. This in vitro study aimed to evaluate the protective efficacy of ESC-sEVs against lead acetate (PbAc)-induced damage in cochlear spiral ganglion neurons (SGNs). Methods: Cochlear SGNs of neonatal rats were primarily cultured and administrated with (i) serum-free medium (control); (ii) 25 μM PbAc; (iii) 0.05 μg/μl ESC-sEVs (ESC-sEVs); (iv) 25 μM PbAc + 0.05 μg/μl ESC-sEVs (PbAc + ESC-sEVs). After treatment, cell viability of SGNs was assessed by CCK-8 assay. The changes in levels of reactive oxygen species, lipid peroxides, and apoptosis were detected by immunofluorescence and flow cytometry. The protective mechanisms of ESC-sEVs against lead-induced SGNs damage were elucidated by RNA sequencing and western blot analysis. Results: The findings revealed that ESC-sEVs significantly increased the viability of SGNs subjected to PbAc exposure. Immunofluorescence and flow cytometry revealed that ESC-sEVs effectively attenuated oxidative stress, lipid peroxidation, and apoptotic processes in PbAc-exposed SGNs. Furthermore, RNA sequencing and western blot analysis demonstrated that ESC-sEVs activated the PI3 K/AKT signaling pathway, which plays a pivotal role in alleviating lead-induced neuronal injury. Conclusion: In conclusion, this study provides the first evidence supporting the therapeutic potential of ESC-sEVs in addressing lead-induced ototoxicity.
- 9 July 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (3)
Open AccessEmbryonic stem cell-derived small extracellular vesicles alleviate lead-induced cochlear spiral ganglion neurons injury by activating PI3 K/AKT signaling pathway
Objective: Embryonic stem cell (ESC)-derived small extracellular vesicles (sEVs) exhibit considerable potential as an innovative therapeutic approach in the fields of regenerative medicine and disease management. This in vitro study aimed to evaluate the protective efficacy of ESC-sEVs against lead acetate (PbAc)-induced damage in cochlear spiral ganglion neurons (SGNs). Methods: Cochlear SGNs of neonatal rats were primarily cultured and administrated with (i) serum-free medium (control); (ii) 25 μM PbAc; (iii) 0.05 μg/μl ESC-sEVs (ESC-sEVs); (iv) 25 μM PbAc + 0.05 μg/μl ESC-sEVs (PbAc + ESC-sEVs). After treatment, cell viability of SGNs was assessed by CCK-8 assay. The changes in levels of reactive oxygen species, lipid peroxides, and apoptosis were detected by immunofluorescence and flow cytometry. The protective mechanisms of ESC-sEVs against lead-induced SGNs damage were elucidated by RNA sequencing and western blot analysis. Results: The findings revealed that ESC-sEVs significantly increased the viability of SGNs subjected to PbAc exposure. Immunofluorescence and flow cytometry revealed that ESC-sEVs effectively attenuated oxidative stress, lipid peroxidation, and apoptotic processes in PbAc-exposed SGNs. Furthermore, RNA sequencing and western blot analysis demonstrated that ESC-sEVs activated the PI3 K/AKT signaling pathway, which plays a pivotal role in alleviating lead-induced neuronal injury. Conclusion: In conclusion, this study provides the first evidence supporting the therapeutic potential of ESC-sEVs in addressing lead-induced ototoxicity.
- 17 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (9) , 581-591
The γ-Actin with pathogenic variants of sites on actin-binding proteins caused earlier onset and more malignant progressive hearing loss
Background: The γ-actin protein, encoded by the ACTG1 gene, is a critical cytoskeletal component in non-muscle cells. Mutations in ACTG1 are associated with autosomal dominant, progressive sensorineural hearing loss (HL), but clinical heterogeneity remains poorly understood. Methods: We identified a novel missense variant, c.981C>G (p.Ile327Met; I327M), in a Chinese family with hereditary HL through whole exome sequencing. Functional analyses were performed to assess ACTG1 mRNA and protein expression, F-actin organisation and subcellular localisation. Structural modelling and electrostatic analysis were used to predict the impact of the I327M substitution. Additionally, we reviewed 35 published ACTG1-related families involving 82 patients to explore genotype-phenotype correlations. Results: The I327M variant resulted in significantly reduced ACTG1 transcript and protein levels, accompanied by disrupted F-actin integrity in patient-derived peripheral blood mononuclear cells. Structural modelling suggested that the variant alters the electrostatic environment near the tropomyosin-binding interface, potentially compromising filament stability. Literature review and comparative analysis revealed that variants located within actin-binding protein (ABP) interaction sites were associated with an earlier onset and more severe progression of HL compared with those located outside ABP-binding domains. Conclusion: The c.981C>G (p.Ile327Met) variant contributes to HL pathogenesis through dual mechanisms involving impaired gene expression and filament destabilisation. This study highlights the clinical relevance of variant location relative to ABP binding regions and provides new insights into genotype-phenotype relationships in ACTG1-associated HL.
- 17 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (9) , 581-591
The γ-Actin with pathogenic variants of sites on actin-binding proteins caused earlier onset and more malignant progressive hearing loss
Background: The γ-actin protein, encoded by the ACTG1 gene, is a critical cytoskeletal component in non-muscle cells. Mutations in ACTG1 are associated with autosomal dominant, progressive sensorineural hearing loss (HL), but clinical heterogeneity remains poorly understood. Methods: We identified a novel missense variant, c.981C>G (p.Ile327Met; I327M), in a Chinese family with hereditary HL through whole exome sequencing. Functional analyses were performed to assess ACTG1 mRNA and protein expression, F-actin organisation and subcellular localisation. Structural modelling and electrostatic analysis were used to predict the impact of the I327M substitution. Additionally, we reviewed 35 published ACTG1-related families involving 82 patients to explore genotype-phenotype correlations. Results: The I327M variant resulted in significantly reduced ACTG1 transcript and protein levels, accompanied by disrupted F-actin integrity in patient-derived peripheral blood mononuclear cells. Structural modelling suggested that the variant alters the electrostatic environment near the tropomyosin-binding interface, potentially compromising filament stability. Literature review and comparative analysis revealed that variants located within actin-binding protein (ABP) interaction sites were associated with an earlier onset and more severe progression of HL compared with those located outside ABP-binding domains. Conclusion: The c.981C>G (p.Ile327Met) variant contributes to HL pathogenesis through dual mechanisms involving impaired gene expression and filament destabilisation. This study highlights the clinical relevance of variant location relative to ABP binding regions and provides new insights into genotype-phenotype relationships in ACTG1-associated HL.
- 13 September 2024
- Published by Elsevier in Toxicology
- Vol. 509, 153938
Ferroptosis contributes to lead-induced cochlear spiral ganglion neurons injury
- 13 September 2024
- Published by Elsevier in Toxicology
- Vol. 509, 153938
Ferroptosis contributes to lead-induced cochlear spiral ganglion neurons injury
- 23 April 2024
- Published by Springer Nature in Applied Intelligence
- Vol. 54 (7) , 5558-5575
Auto-metric distribution propagation graph neural network with a meta-learning strategy for diagnosis of otosclerosis
- 23 April 2024
- Published by Springer Nature in Applied Intelligence
- Vol. 54 (7) , 5558-5575
Auto-metric distribution propagation graph neural network with a meta-learning strategy for diagnosis of otosclerosis
- Open Access
- 16 April 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (4) , 1-14
Construction and validation of a folate metabolism-related gene signature for predicting prognosis in HNSCC
Purpose: Metabolic reprogramming is currently considered a hallmark of tumor and immune development. It is obviously of interest to identify metabolic enzymes that are associated with clinical prognosis in head and neck squamous cell carcinomas (HNSCC). Methods: Candidate genes were screened to construct folate metabolism scores by Cox regression analysis. Functional enrichment between high- and low-folate metabolism groups was explored by GO, KEGG, GSVA, and ssGSEA. EPIC, MCPcounter, and xCell were utilized to explore immune cell infiltration between high- and low-folate metabolism groups. Relevant metabolic scores were calculated and visually analyzed by the “IOBR” software package. Results: To investigate the mechanism behind metabolic reprogramming of HNSCC, 2886 human genes associated with 86 metabolic pathways were selected. Folate metabolism is significantly enriched in HNSCC, and that the six-gene (MTHFD1L, MTHFD2, SHMT2, ATIC, MTFMT, and MTHFS) folate score accurately predicts and differentiates folate metabolism levels. Reprogramming of folate metabolism affects CD8T cell infiltration and induces immune escape through the MIF signaling pathway. Further research found that SHMT2, an enzyme involved in folate metabolism, inhibits CD8T cell infiltration and induces immune escape by regulating the MIF/CD44 signaling axis, which in turn promotes HNSCC progression. Conclusions: Our study identified a novel and robust folate metabolic signature. A folate metabolic signature comprising six genes was effective in assessing the prognosis and reflecting the immune status of HNSCC patients. The target molecule of folate metabolic reprogramming, SHMT2, probably plays a very important role in HNSCC development and immune escape.
- 16 April 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (4) , 1-14
Open AccessConstruction and validation of a folate metabolism-related gene signature for predicting prognosis in HNSCC
Purpose: Metabolic reprogramming is currently considered a hallmark of tumor and immune development. It is obviously of interest to identify metabolic enzymes that are associated with clinical prognosis in head and neck squamous cell carcinomas (HNSCC). Methods: Candidate genes were screened to construct folate metabolism scores by Cox regression analysis. Functional enrichment between high- and low-folate metabolism groups was explored by GO, KEGG, GSVA, and ssGSEA. EPIC, MCPcounter, and xCell were utilized to explore immune cell infiltration between high- and low-folate metabolism groups. Relevant metabolic scores were calculated and visually analyzed by the “IOBR” software package. Results: To investigate the mechanism behind metabolic reprogramming of HNSCC, 2886 human genes associated with 86 metabolic pathways were selected. Folate metabolism is significantly enriched in HNSCC, and that the six-gene (MTHFD1L, MTHFD2, SHMT2, ATIC, MTFMT, and MTHFS) folate score accurately predicts and differentiates folate metabolism levels. Reprogramming of folate metabolism affects CD8T cell infiltration and induces immune escape through the MIF signaling pathway. Further research found that SHMT2, an enzyme involved in folate metabolism, inhibits CD8T cell infiltration and induces immune escape by regulating the MIF/CD44 signaling axis, which in turn promotes HNSCC progression. Conclusions: Our study identified a novel and robust folate metabolic signature. A folate metabolic signature comprising six genes was effective in assessing the prognosis and reflecting the immune status of HNSCC patients. The target molecule of folate metabolic reprogramming, SHMT2, probably plays a very important role in HNSCC development and immune escape.
- 20 February 2024
- Published by Springer Nature in Human Cell
- Vol. 37 (3) , 817-831
Identification of a family with van der Hoeve’s syndrome harboring a novel COL1A1 mutation and generation of patient-derived iPSC lines and CRISPR/Cas9-corrected isogenic iPSCs
Van der Hoeve’s syndrome, also known as osteogenesis imperfecta (OI), is a genetic connective tissue disorder characterized by fragile, fracture-prone bone and hearing loss. The disease is caused by a gene mutation in one of the two type I collagen genes COL1A1 or COL1A2. In this study, we identified a novel frameshift mutation of the COL1A1 gene (c.1607delG) in a family with OI using whole-exome sequencing, bioinformatics analysis and Sanger sequencing. This mutation may lead to the deletion of a portion of exon 23 and the generation of a premature stop codon in the COL1A1 gene. To further investigate the impact of this mutation, we established two induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells of OI patients carrying a novel mutation in the COL1A1 gene. Osteoblasts (OB) derived from OI-iPSCs exhibited reduced production of type I collagen and diminished ability to differentiate into osteoblasts. Using a CRISPR-based homology-directed repair strategy, we corrected the OI disease-causing COL1A1 novel mutations in iPSCs generated from an affected individual. Our results demonstrated that the diminished expression of type I collagen and osteogenic potential were enhanced in OB induced from corrected OI-iPSCs compared to those from OI-iPSCs. Overall, our results provide new insights into the genetic basis of Van der Hoeve’s syndrome and highlight the potential of iPSC technology for disease modeling and therapeutic development.
- 20 February 2024
- Published by Springer Nature in Human Cell
- Vol. 37 (3) , 817-831
Identification of a family with van der Hoeve’s syndrome harboring a novel COL1A1 mutation and generation of patient-derived iPSC lines and CRISPR/Cas9-corrected isogenic iPSCs
Van der Hoeve’s syndrome, also known as osteogenesis imperfecta (OI), is a genetic connective tissue disorder characterized by fragile, fracture-prone bone and hearing loss. The disease is caused by a gene mutation in one of the two type I collagen genes COL1A1 or COL1A2. In this study, we identified a novel frameshift mutation of the COL1A1 gene (c.1607delG) in a family with OI using whole-exome sequencing, bioinformatics analysis and Sanger sequencing. This mutation may lead to the deletion of a portion of exon 23 and the generation of a premature stop codon in the COL1A1 gene. To further investigate the impact of this mutation, we established two induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells of OI patients carrying a novel mutation in the COL1A1 gene. Osteoblasts (OB) derived from OI-iPSCs exhibited reduced production of type I collagen and diminished ability to differentiate into osteoblasts. Using a CRISPR-based homology-directed repair strategy, we corrected the OI disease-causing COL1A1 novel mutations in iPSCs generated from an affected individual. Our results demonstrated that the diminished expression of type I collagen and osteogenic potential were enhanced in OB induced from corrected OI-iPSCs compared to those from OI-iPSCs. Overall, our results provide new insights into the genetic basis of Van der Hoeve’s syndrome and highlight the potential of iPSC technology for disease modeling and therapeutic development.
- Open Access
- 28 September 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1292836
Editorial: Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss
Editorial: Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss
- 28 September 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1292836
Open AccessEditorial: Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss
Editorial: Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss